Abstract
The methylarginines asymmetric dimethylarginine (ADMA) and monomethylarginine (L-NMMA) are endogenously formed inhibitors of nitric oxide synthases (NOS), which have extensively been investigated as risk markers and used as pharmacological tools to study the L-arginine-nitric oxide (NO) pathway in vitro and in vivo. It is the aim of the present review to summarize the clinical and experimental data on the pharmacological properties that are of relevance when planning and conducting experiments and clinical studies involving methylarginines. Key pharmacodynamic and pharmacokinetic data including IC50 values of ADMA and L-NMMA for NOS isoforms and transport proteins, as well as metabolism by dimethylarginine dimethylaminohydrolases (DDAH1 and DDAH2) and alanine-glyoxylate aminotransferase 2 (AGXT2) are discussed.
Keywords: Asymmetric dimethylarginine (ADMA), Symmetric dimethylarginine (SDMA), Monomethylarginine (L-NMMA), Nitric oxide synthase (NOS), Dimethylarginine dimethylaminohydrolase (DDAH), Alanine-glyoxylate aminotransferase 2 (AGXT2).
Current Pharmaceutical Design
Title:Pharmacology and Clinical Pharmacology of Methylarginines Used as Inhibitors of Nitric Oxide Synthases
Volume: 20 Issue: 22
Author(s): Anja Kittel and Renke Maas
Affiliation:
Keywords: Asymmetric dimethylarginine (ADMA), Symmetric dimethylarginine (SDMA), Monomethylarginine (L-NMMA), Nitric oxide synthase (NOS), Dimethylarginine dimethylaminohydrolase (DDAH), Alanine-glyoxylate aminotransferase 2 (AGXT2).
Abstract: The methylarginines asymmetric dimethylarginine (ADMA) and monomethylarginine (L-NMMA) are endogenously formed inhibitors of nitric oxide synthases (NOS), which have extensively been investigated as risk markers and used as pharmacological tools to study the L-arginine-nitric oxide (NO) pathway in vitro and in vivo. It is the aim of the present review to summarize the clinical and experimental data on the pharmacological properties that are of relevance when planning and conducting experiments and clinical studies involving methylarginines. Key pharmacodynamic and pharmacokinetic data including IC50 values of ADMA and L-NMMA for NOS isoforms and transport proteins, as well as metabolism by dimethylarginine dimethylaminohydrolases (DDAH1 and DDAH2) and alanine-glyoxylate aminotransferase 2 (AGXT2) are discussed.
Export Options
About this article
Cite this article as:
Kittel Anja and Maas Renke, Pharmacology and Clinical Pharmacology of Methylarginines Used as Inhibitors of Nitric Oxide Synthases, Current Pharmaceutical Design 2014; 20 (22) . https://dx.doi.org/10.2174/13816128113196660750
DOI https://dx.doi.org/10.2174/13816128113196660750 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Insight of Alpha-amylase Inhibitors as a Valuable Tool in the Management of Type 2 Diabetes Mellitus
Current Diabetes Reviews Metabolic and Cardiovascular Ageing Indices in Relation to Glycated Haemoglobin in Healthy and Diabetic Subjects
Current Aging Science Polyethylene Glycol Acts as a Mechanistic Stabilizer of L-asparaginase: A Computational Probing
Medicinal Chemistry Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Potential Therapeutic Strategies of Regenerative Medicine for Renal Failure
Current Stem Cell Research & Therapy Membrane Domains and the “Lipid Raft” Concept
Current Medicinal Chemistry New Developments in Systemic Therapy for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Cystic Echinococcosis: Aspects of Immune Response, Immunopathogenesis and Immune Evasion from the Human Host
Endocrine, Metabolic & Immune Disorders - Drug Targets Serum Hepcidin, the Hepcidin/Ferritin Ratio and the Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Dietary Melatonin Protects Against Behavioural, Metabolic, Oxidative, and Organ Morphological Changes in Mice that are Fed High-Fat, High- Sugar Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipids and Their Derivatives: By-Products Used as Essential Building Blocks for Modern Drug Delivery Systems
Current Drug Targets Nutritional Modulation of Terminal End Buds: Its Relevance to Breast Cancer Prevention
Current Cancer Drug Targets Synthesis and Biological Activity of 3-(substitutedphenyl)- 6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Cardiovascular Disease and Dyslipidemia: Beyond LDL
Current Pharmaceutical Design Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Vascular Damage In Systemic Sclerosis)
Current Rheumatology Reviews Cardiovascular Control After Spinal Cord Injury
Current Vascular Pharmacology Pegaptanib Sodium for the Treatment of Proliferative Diabetic Retinopathy and Diabetic Macular Edema
Current Diabetes Reviews Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials
Current Drug Targets